Compare Cassava Sciences Inc (FLNA) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hyatt Hotels Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Hyatt Hotels Corporation trades at $193.03 (market cap $17.98B). The key difference: Hyatt Hotels Corporation is far larger — about 338.4× Cassava Sciences Inc's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | H | |
|---|---|---|
Market Cap | $53.14M | $17.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $202.09 |
52-Week Low | $1.09 | $135.01 |
Enterprise Value | -$33.43M | $21.83B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Hyatt Hotels (H) trades at $189.70, up 2.7% on the day, near its consensus price target of $198.20. The stock shows a neutral technical signal with bullish moving averages. Fundamentally, the company reported mixed Q1 2026 earnings, beating estimates with $0.63 EPS versus $0.565 expected, but faces profitability challenges with a negative net income margin of -0.48% for 2025. Recent corporate developments include expansion plans for a new Hyatt Regency in Tucson and active participation in investor conferences, signaling growth initiatives.
The outlook balances analyst optimism with fundamental headwinds. Wall Street maintains a 'Hold' consensus (52.08% Hold, 37.5% Buy) with a $198.20 price target, suggesting modest upside. Investment opportunities include strategic expansion and premium positioning, but risks include inconsistent profitability, negative ROE (-1.02%), and elevated leverage with debt-to-asset ratio rising to 31.2% in 2025. The stock's valuation appears rich at a P/E of 31.36, requiring sustained earnings improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
